PD-L1 expression can be evaluated using different scoring systems, such as the Tumor Proportion Score (TPS) and the Combined Positive Score (CPS), each with distinct clinical cut-offs specific to the assay, tumor type, and therapeutic agent. Here, CD274 is linked to neoplasm.